Genomic Surveillance Reveals Emergence and Spread of Macrolide-Resistant Mycoplasma pneumoniae in Australia During the 2023–2024 Epidemic
The Journal of Infectious Diseases · 03.08.2026 · 234 (1) · e121-e130
DOI: 10.1093/infdis/jiag163 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 21.03.2026. Verfasst von Kingsley King-Gee Tam und 26 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Infectious Diseases and Microbiology-Public Health, Westmead Hospital, Westmead, New South Wales, Australia. Hauptthemen laut MEDLINE: Mycoplasma pneumoniae, Macrolides, Pneumonia, Mycoplasma, Drug Resistance, Bacterial. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NSW Health, National Health and Medical Research Council.
Abstract (Originalsprache)
Background
The resurgence of Mycoplasma pneumoniae, first reported in China in 2023, was attributed to waning postpandemic immunity with increases in macrolide-resistant M. pneumoniae (MRMP) (> 80%). In Australia, infections peaked in early 2024, particularly among children under 15 years. While MRMP remains low in Europe, North America, and Australia (< 5%), limited routine testing restricts understanding of resistance dynamics. As macrolides are first-line therapy in many settings, MRMP surveillance is essential for guiding empirical treatment.
Methods
We applied a capture-based targeted metagenomic sequencing (targeted next-generation sequencing [tNGS]) to polymerase chain reaction (PCR)-positive M. pneumoniae specimens (n = 356) from across Australia. This approach enabled whole-genome recovery and MRMP detection directly from clinical specimens, without culture. MRMP detections were benchmarked against PCR and data were analyzed to assess associations between resistance and health care utilization.
Results
This is the first genomics-informed national study of M. pneumoniae in Australia. We recovered 124 high-quality genomes, revealing a genetically diverse population with cocirculation of P1 type 1 (69%) and type 2 (31%). MRMP was identified in 13% of genomes, all belonging to clades that prior to 2024 had only been reported in Asia (ST3 and ST14). MRMP cases were geographically widespread, suggesting importation and local transmission. Unlike reports from China, macrolide-susceptible clades (ST3, ST7, ST17, and ST20) predominated (87%) and were associated with significantly lower health care utilization compared to MRMP cases.
Conclusions
Our findings demonstrate the utility of tNGS for genomic epidemiology and highlight the need for MRMP surveillance. Although macrolides remain effective in Australia, emerging MRMP strains require close monitoring to inform treatment guidelines and antimicrobial stewardship.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Infectious Diseases and Microbiology-Public Health, Westmead Hospital, Westmead, New South Wales, Australia.
- School of Medical Sciences, Faculty of Medicine and Health, Sydney Infectious Diseases Institute, The University of Sydney, Westmead, New South Wales, Australia.
- Centre for Infectious Diseases and Microbiology Laboratory Services, NSW Health Pathology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, New South Wales, Australia.
- Douglass Hanly Moir Pathology, A Sonic Healthcare Practice, Macquarie Park, New South Wales, Australia.
- Sullivan Nicolaides Pathology, A Sonic Healthcare Practice, Bowen Hills, Queensland, Australia.
- SA Pathology, Adelaide, South Australia, Australia.
ORCID-Profile: Kingsley King-Gee Tam, Carl J E Suster, Winkie Fong, Tanya Golubchik, Neisha Jeoffreys, Jennifer Robson, Maryza Graham, David Speers, Louise Cooley, Kerri Basile, Vitali Sintchenko, Jen Kok, Rebecca J Rockett
Förderung
- NSW Health
- National Health and Medical Research Council
Zitieren
APA
Tam, K. K., Suster, C. J. E., Fong, W., Golubchik, T., Sivalingam, V., Jeoffreys, N., Tay, E., Ko, D., Wehrhahn, M. C., Ginn, A. N., Robson, J., Gardner, I., Papanicolas, L. E., Kennedy, K., Graham, M., Tran, T., Speers, D., Cooley, L., Baird, R. W., …, & Rockett, R. J. (2026). Genomic Surveillance Reveals Emergence and Spread of Macrolide-Resistant Mycoplasma pneumoniae in Australia During the 2023–2024 Epidemic. The Journal of Infectious Diseases, 234(1), e121-e130. https://doi.org/10.1093/infdis/jiag163
Vancouver
Tam KK, Suster CJE, Fong W, Golubchik T, Sivalingam V, Jeoffreys N, et al. Genomic Surveillance Reveals Emergence and Spread of Macrolide-Resistant Mycoplasma pneumoniae in Australia During the 2023–2024 Epidemic. The Journal of Infectious Diseases. 2026;234(1):e121-e130. doi:10.1093/infdis/jiag163
BibTeX
@article{Tam2026,
author = {Tam, Kingsley King-Gee and Suster, Carl J E and Fong, Winkie and Golubchik, Tanya and Sivalingam, Varsha and Jeoffreys, Neisha and Tay, Enoch and Ko, Danny and Wehrhahn, Michael C and Ginn, Andrew N and Robson, Jennifer and Gardner, Indya and Papanicolas, Lito E and Kennedy, Karina and Graham, Maryza and Tran, Thomas and Speers, David and Cooley, Louise and Baird, Rob W and Meumann, Ella M and Harbidge, Jaimee and Campbell, Stuart and Basile, Kerri and Chen, Sharon C A and Sintchenko, Vitali and Kok, Jen and Rockett, Rebecca J},
title = {Genomic Surveillance Reveals Emergence and Spread of Macrolide-Resistant Mycoplasma pneumoniae in Australia During the 2023–2024 Epidemic},
journal = {The Journal of Infectious Diseases},
year = {2026},
volume = {234},
number = {1},
pages = {e121--e130},
doi = {10.1093/infdis/jiag163}
}
EUVIMED